• Mira Pharmaceuticals posted a net loss of $1.15 million, narrowing from $1.78 million a year earlier, while loss per share improved to $0.03 from $0.11.
• Operating costs fell to $1.1 million from $1.81 million, as general and administrative expense dropped to $578,698 from $1.49 million.
• Research and development spending climbed to $524,781 from $314,404.
• Cash declined to $4.82 million from $6.35 million at Dec. 31, while short-term investments edged down to $4.59 million from $4.68 million.
• Ketamir-2 completed Phase 1 dosing and is being advanced toward a Phase 2a CIPN study in first half 2026, while MIRA-55 and SKNY-1 remained in preclinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023005), on May 14, 2026, and is solely responsible for the information contained therein.